Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05319236
Other study ID # R-DND-11 BRIDGE Study_CIP
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 16, 2022
Est. completion date June 30, 2023

Study information

Verified date February 2023
Source Gabi SmartCare
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Subjects will use the Gabi system on a daily basis for 3 months, each time the subject is resting or asleep. The Gabi system will recording the SpO2, pulse rate, respiratory rate and movements of the subject. The objective of this study is to perform a first assessment of the range of most potentially clinically relevant indications for use of the Gabi system for children < 6 years old with underlying medical conditions. This is performed by asking HCPs to review the data measured by the Gabi system after taking a medical decision independently from the Gabi data and to assess the potential clinical utility of the Gabi system. The usability of the system will also be assessed throughout questionnaires filled out by the HCPs and by the caregivers. *During this study, the data collected by the Gabi system are not intended to be used by caregivers or HCPs to take any (medical) decisions.


Recruitment information / eligibility

Status Completed
Enrollment 101
Est. completion date June 30, 2023
Est. primary completion date November 30, 2022
Accepts healthy volunteers No
Gender All
Age group N/A to 5 Years
Eligibility Inclusion Criteria: 1. Infants and children < 6 years old. 2. Subjects who present at least one of the following underlying medical conditions: 1. Subjects who underwent a congenital cardiac or cardiopulmonary surgery recently and could benefit from an additional post-surgery monitoring at home, per the investigator's opinion. 2. Subjects at risk awaiting surgery. 3. Subjects hospitalized following a severe respiratory condition within the past 2 weeks requiring invasive or non-invasive ventilation or oxygen therapy. 4. Subjects hospitalized following a severe cardiovascular condition within the past 2 weeks, including severe heart failure, tachycardia or bradycardia. 5. Subjects with chronic respiratory disease, such as asthma, developmental or cardiovascular conditions who could benefit from medical monitoring at home, per the investigator's opinion. 6. Subjects with chronic respiratory support at home. 7. Premature babies who required intensive neonatal care. 8. Subjects hospitalized following a Brief Resolved Unexpected Event (BRUE) within the past 2 weeks. 9. A clinical risk identified by the investigator which justifies the potential benefit of having a Gabi system used by the subject 3. Subject is (or is willing to be) followed up by an HCP of the investigation site during the duration of the study. 4. Signed informed consent form prior to performing any study specific procedure. 5. Willing and likely (based on the investigator's judgement) to comply with all study requirements. Exclusion Criteria: 1. Weight < 2.5 kg. 2. Subject presenting an anatomical limitation that would prevent the use of the Gabi system. 3. Subjects presenting a motor disorder that would prevent the use of the Gabi system (with the exception of epilepsy ). 4. Subjects participating in another interventional clinical study (with the exception of registries), which may have an impact on this study outcomes, based on the investigator's judgement.

Study Design


Intervention

Device:
Gabi System
See arm description

Locations

Country Name City State
Belgium Universitair Ziekenhuis Antwerpen (UZA) Antwerp
Belgium Clinique CHC Montlégia Liège
United States Columbia University Irving Medical Center New York New York
United States Children's National Hospital Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Gabi SmartCare

Countries where clinical trial is conducted

United States,  Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Utility Define the range of most potentially clinically significant indications for use of the Gabi system based on the Gabi system clinical utility assessment per medical condition, assessed throughout Medical Decision Questionnaires and Clinical Utility Questionnaires. Assessed at the end of the 3-month period for each participant
Primary Caregiver Usability Assess the usability of the Gabi system from the point of view of the caregivers through a Usability Questionnaire. Assessed at the end of the 3-month period for each participant
Primary HCP Usability Assess the usability of the Gabi system from the point of view of the HCPs through a Usability Questionnaire. Assessed at the end of the 3-month period for each participant
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)